Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
Dina AbushanabSalma ChbibRasha KaddouraMoza Al HailPalli Valappila Abdul RoufWessam El-KassemJassim ShahRamesh NairDaoud Al-BadriyehPublished in: Journal of medical economics (2024)
Adding dapagliflozin to SoC is likely to be a cost-saving therapy for patients with HFrEF and without T2DM in Qatar.